<DOC>
	<DOCNO>NCT00420849</DOCNO>
	<brief_summary>This multi-centre , single-arm treatment study combine lenalidomide plus high dose dexamethasone . Subjects qualify participation receive lenalidomide plus high dose dexamethasone 4 week cycle . Subjects see every 2 week first 3 cycle therapy every 4 week third cycle disease progression document , study drug discontinue reason lenalidomide become commercially available indication . Assessments safety quality life perform study .</brief_summary>
	<brief_title>A Multicentre , Single-arm , Open-label Safety Study Lenalidomide Plus Dexamethasone Previously Treated Subjects With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Must diagnose multiple myeloma progress least 2 cycle antimyeloma treatment relapse progressive disease treatment . Subjects must discontinue antimyeloma drug nondrug therapy prior first dose study drug exception radiation therapy initiate prior baseline . Females childbearing potential must agree use two reliable form contraception simultaneously practice complete abstinence . Pregnant lactating female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>